Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV
Completed · Phase 2 · Has a placebo group
Conditions studied: HIV Infection, HIV Infections
In brief
This study was designed to test the hypothesis that treatment of HIV infected subjects with losartan, an agent with specific anti-inflammatory and anti-fibrotic actions, will: 1. reverse existing lymphoid tissue fibrosis, 2. restore lymphoid tissue architecture, 3. increase the number and improve the function of peripheral and lymphatic CD4 T cells, 4. decrease levels of systemic immune activation (IA), 5. decrease size of the HIV reservoir, and 6. be safe and well tolerated.
Key facts
- Study ID
- NCT01852942
- Run by
- University of Minnesota
- People needed
- 52
- Starts
- 2014-09-01
- Expected to finish
- 2019-07-16
- Last updated by the study team
- 2020-12-11
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: accepted.
Where it is running
- University of Minnesota, Division of Infectious Diseases — Minneapolis, Minnesota, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.